Login to myESAIC Membership
Back

About

The ESAIC is dedicated to supporting professionals in anaesthesiology and intensive care by serving as the hub for development and dissemination of valuable educational, scientific, research, and networking resources.


Back

Congresses

The ESAIC hosts the Euroanaesthesia and Focus Meeting congresses that serve as platforms for cutting-edge science and innovation in the field. These events bring together experts, foster networking, and facilitate knowledge exchange in anaesthesiology, intensive care, pain management, and perioperative medicine. Euroanaesthesia is one of the world’s largest and most influential scientific congresses for anaesthesia professionals. Held annually throughout Europe, our congress is a contemporary event geared towards education, knowledge exchange and innovation in anaesthesia, intensive care, pain and perioperative medicine, as well as a platform for immense international visibility for scientific research.


Back

Professional Growth

The ESAIC's mission is to foster and provide exceptional training and educational opportunities. The ESAIC ensures the provision of robust and standardised examination and certification systems to support the professional development of anaesthesiologists and to ensure outstanding future doctors in the field of anaesthesiology and intensive care.


Back

Research

The ESAIC aims to advance patient outcomes and contribute to the progress of anaesthesiology and intensive care evidence-based practice through research. The ESAIC Clinical Trial Network (CTN), the Academic Contract Research Organisation (A-CRO), the Research Groups and Grants all contribute to the knowledge and clinical advances in the peri-operative setting.


Back

EU Projects

The ESAIC is actively involved as a consortium member in numerous EU funded projects. Together with healthcare leaders and practitioners, the ESAIC's involvement as an EU project partner is another way that it is improving patient outcomes and ensuring the best care for every patient.


image of a stethoscope laying on the european flag
Back

Patient Safety

The ESAIC aims to promote the professional role of anaesthesiologists and intensive care physicians and enhance perioperative patient outcomes by focusing on quality of care and patient safety strategies. The Society is committed to implementing the Helsinki Declaration and leading patient safety projects.


Back

Sustainability

The ESAIC is committed to implementing the Glasgow Declaration and drive initiatives towards greater environmental sustainability across anaesthesiology and intensive care in Europe.


Back

Partnerships

The ESAIC works in collaboration with industry, national societies, and specialist societies to promote advancements in anaesthesia and intensive care. The Industry Partnership offers visibility and engagement opportunities for industry participants with ESAIC members, facilitating understanding of specific needs in anaesthesiology and in intensive care. This partnership provides resources for education and avenues for collaborative projects enhancing science, education, and patient safety. The Specialist Societies contribute to high-quality educational opportunities for European anaesthesiologists and intensivists, fostering discussion and sharing, while the National Societies, through NASC, maintain standards, promote events and courses, and facilitate connections. All partnerships collectively drive dialogue, learning, and growth in the anaesthesiology and intensive care sector.


Back

Guidelines

Guidelines play a crucial role in delivering evidence-based recommendations to healthcare professionals. Within the fields of anaesthesia and intensive care, guidelines are instrumental in standardizing clinical practices and enhancing patient outcomes. For many years, the ESAIC has served as a pivotal platform for facilitating continuous advancements, improving care standards and harmonising clinical management practices across Europe.


Back

Publications

With over 40 years of publication history, the EJA (European Journal of Anaesthesiology) has established itself as a highly respected and influential journal in its field. It covers a wide range of topics related to anaesthesiology and intensive care medicine, including perioperative medicine, pain management, critical care, resuscitation, and patient safety.


Back

Membership

Becoming a member of ESAIC implies becoming a part of a vibrant community of nearly 8,000 professionals who exchange best practices and stay updated on the latest developments in anaesthesiology, intensive care and perioperative medicine. ESAIC membership equips you with the tools and resources necessary to enhance your daily professional routine, nurture your career growth, and play an active role in advancing anaesthesiology, intensive care and perioperative medicine.


Membership opportunities
at the ESAIC

woman showing another woman something on her computer in a hospital

Newsletter 2025

COVend: Advancing FX06 for ARDS with Multi-Omic and AI Technologies

COVend Logo

The COVend consortium is making significant strides in medical research with the launch of the IXION 2.0 clinical trial, which has shifted focus from COVID-19 to examining FX06’s effectiveness for acute respiratory distress syndrome (ARDS). This trial involves international collaboration and innovative methodologies, such as AI-driven analysis and advanced cell biology techniques, to provide personalised treatment approaches. COVend’s groundbreaking research has been showcased in prestigious forums like the EMBL Conference, 7th European Congress of Immunology and detailed in Horizon magazine. The consortium’s work, particularly by researchers at University College Dublin, is providing new perspectives on the potential of FX06. Discover more about these exciting developments in their featured articles.

Major Milestone Reached: COVend’s IXION 2.0 Trial Fully Launched and Accelerating Progress

The EU-funded COVend consortium kicked off the IXION 2.0 clinical trial in March 2024, enrolling the first patients across partnering clinical sites in Germany, France, Spain, Lithuania, and Romania. The trial closed in December 2024. Initially aimed at treating mild to severe COVID-19 in high-risk individuals, the trial has now pivoted to explore the drug’s efficacy for ARDS patients. This new direction is led by COVend’s scientific coordinator, Prof. Kai Zacharowski, MD PhD ML FRCA FESAIC, head of the Department of Anaesthesiology, Intensive Care Medicine and Pain Therapy at Goethe University Hospital Frankfurt and Dr. Petra Wuelfroth, COVend’s Innovation Manager and co-founder of F4 Pharma in Vienna. The consortium and clinical trial were restructured in record time reflecting a strong commitment to advancing innovative medical research for critical health conditions. The IXION 2.0 study is an exploratory, randomised, placebo-controlled, double-blind, parallel phase II clinical trial, delivering the results on patient-relevant outcomes. An exploratory molecular analysis of the proteins, lipids, and metabolites in the blood of the study participants (known as ‘multi-omic analysis’) and artificial intelligence will identify subtle pathophysiological differences between patient groups. Advanced cell biology methods using endothelial cell lines will uncover the molecular mechanism of FX06, contributing to knowledge-based trust and transparency in medicine and potentially paving the way for further life-saving applications. In addition to scientific research, the COVend consortium is also dedicated to the evaluation of FX06 from a health economic perspective. By developing a dynamic model, the socio-economic benefits and cost-effectiveness of FX06 will be assessed to ensure its practical feasibility in healthcare.

COVend in the Spotlight: Recent Highlights and Appearances

The COVend partners from University College Dublin and Systems Biology Ireland have showcased pioneering research on how the fibrin-derived peptide FX06 can protect human pulmonary endothelial cells from cytokines triggered by COVID-19 at the EMBL Conference, EMBO Workshop: Building Networks 2024 in Barcelona, Spain on 6-8 May, 2024. A team researcher, Zhiran Wang, presented a dedicated poster on this innovative research. In September 2024, Zhiran Wang and her supervisor and one of COVend’s PIs, Prof Günther Eissner, participated in the 7th European Congress of Immunology in Dublin, further sharing their cutting-edge findings. COVend has also been featured in an article in Horizon magazine. Titled “Breathing Easier: Nature-Inspired Treatments Could Relieve Acute Respiratory Distress,” the article highlights the groundbreaking potential of COVend’s approach to providing new insights into the treatment of ARDS. Additionally, COVend was showcased at the Euroanaesthesia 2024 Congress held in Munich, Germany, on 25-27 May 2024.

Unlocking the Potential of FX06: An Interview with the UCD Systems Biology Ireland Team on Their Research in COVend

University College Dublin and Systems Biology Ireland focus on developing new therapeutic approaches to disease through a combination of traditional wet-lab experimental analyses and cutting-edge computational modelling and simulation. One of our key COVend researchers, Prof Günther Eissner, supervises a dedicated group of researchers who study the impact of COVID-19-triggered cytokines on human microvascular pulmonary endothelial cells. Günther’s team can gain detailed insights into the immune response, viability, stress signalling and other cellular processes. The researchers have made significant progress in understanding how the drug FX06 can counteract the pro-inflammatory effects of a SARS-CoV2 infection and the underlying mechanisms behind its action. These mechanisms are also relevant for the progression of ARDS and other conditions associated with endothelial inflammation and capillary leakage. We had the opportunity to speak with Günther and his team to learn more about their research. Follow the link to read the full interview with Günther Eissner and Zhiran Wang.sment and gathering requirements for the European ICU Data Space.

Author

  • Anastasiia Aksonova, COVend Communications Manager
EU Disclaimer 01